E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Extracranial germ cell tumours |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To stratify and reduce treatment for patients with extracranial germ cell tumours according to prognostic factors derived from analysis of UKCCSG Study GC8901 (GCII) whilst maintaining event free survival (EFS)
|
|
E.2.2 | Secondary objectives of the trial |
To continue to treat newly diagnosed patients with extracranial germ cell tumours requiring chemotherapy with a Carboplatin based strategy To develop a common strategy for the treatment of patients with recurrent or progressive extracranial germ cell tumours To register all cases of mature and immature teratoma To develop a common strategy for the management of immature and mature teratoma including follow-up strategies to permit early detection of yolk sac recurrence
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Newly diagnosed extracranial malignant germ cell tumour or mature/immature teratoma. All tumours must be histologically proven with or without raised AFP/HCG. Exceptional cases with unequivocally raised AFP/HCG and where the risk of biopsy is felt to be high can be diagnosed on clinical grounds, imaging and markers. ii) Patients with relapsed or progressing extracranial MGCT if previously treated with JEB chemotherapy iii) Age 0 – 18 years (i.e. up to but not including 18th birthday - but see Guidelines for Adolescents Section 8.3.4) iv) Blood count with neutrophil count > 1 x 109/L and platelet count > 100 x 109/L v) Liver function: Bilirubin < 2 x upper limit laboratory normal, ALT < 3 x upper limit laboratory normal vi) National and local ethical approval vii) Written and verbal informed patient/parent consent
|
|
E.4 | Principal exclusion criteria |
Absence of inclusion criteria plus: i) Pregnant or lactating females ii) Intracranial GCTs iii) Patients receiving prior chemotherapy other than JEB. Patients relapsing following JEB are eligible for the relapse strategy (see above).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Low risk patients: Relapse rate will be monitored, based on the 12-month event rate (defined as relapse, progression or death). After the first 10 patients are included in the study with a minimum of 12 months’ follow up, analysis will be carried out. The stopping boundary will be crossed if 7 or more than 7 events are observed. If 6 or fewer than 6 events are observed accrual will continue and a second analysis will be carried out when a further 10 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 10 or more than 10 events are observed. If 9 or fewer than 9 events are observed accrual will continue and a third analysis will be carried out when a further 10 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 12 or more than 12 events are observed. If 11 or fewer than 11 events are observed accrual will continue and a fourth analysis will be carried out when a further 10 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 15 or more than 15 events are observed. If 14 or fewer than 14 events are observed accrual will continue and a final analysis will be carried out when the 50 patients are included in the study and have a minimum of 12 months’ follow up. The relapse rate would be significantly higher than previously if 17 or more than 17 events are observed . Intermediate risk patients: It is anticipated 4 patients per year would be included in the intermediate risk group of patients. The reduction in the number of courses of chemotherapy may lead to a higher relapse rate and so a stopping rule to prevent an excess of relapses or progressions in patients entering the study will be used. The rule is based on monitoring the 12-month event rate. After the first 4 patients are included in the study with a minimum of 12 months’ follow up, analysis will be carried out. The stopping boundary will be crossed if 3 or more than 3 events are observed. If 2 or fewer than 2 events are observed accrual will continue and a second analysis will be carried out when a further 4 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 3 or more than 3 events are observed. If 2 or fewer than 2 events are observed accrual will continue and a third analysis will be carried out when a further 4 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 3 or more than 3 events are observed. If 2 or fewer than 2 events are observed accrual will continue and a fourth analysis will be carried out when a further 4 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 3 or more than 3 events are observed. If 2 or fewer than 2 events are observed accrual will continue and a final analysis will be carried out when the 20 patients are included in the study and have a minimum of 12 months’ follow up. The relapse rate would be significantly higher than before if 4 or more than 4 events are observed. High risk patients: It is anticipated 7 patients per year would be included in the high-risk group of patients. The protocol treatment for high-risk patients is similar to before, but the relapse rate will be monitored, with a stopping rule to prevent an excess of relapses or progressions in these patients. The rule is based on monitoring the 12-month event rate. After the first 7 patients are included in the study with a minimum of 12 months’ follow up, analysis will be carried out. The stopping boundary will be crossed if 7 events are observed . If 6 or fewer than 6 events are observed accrual will continue and a second analysis will be carried out when a further 7 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 9 or more than 9 events are observed. If 8 or fewer than 8 events are observed accrual will continue and a third analysis will be carried out when a further 7 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 11 or more than 11 events are observed. If 10 or fewer than 10 events are observed accrual will continue and a fourth analysis will be carried out when a further 7 patients are included in the study and have a minimum of 12 months’ follow up. The stopping boundary will be crossed if 13 or more than 13 events are observed. If 12 or fewer than 12 events are observed accrual will continue and a final analysis will be carried out when the 35 patients are included in the study and have a minimum of 12 months’ follow up. The relapse rate would be significantly higher than before if 15 or more than 15 events are observed.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Accrual of target number of patients |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |